Celltrion, Inc. - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Celltrion, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Celltrion, Inc. - Product Pipeline Review - 2015', provides an overview of the Celltrion, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celltrion, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Celltrion, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Celltrion, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Celltrion, Inc.'s pipeline products

Reasons to buy

- Evaluate Celltrion, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Celltrion, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Celltrion, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Celltrion, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celltrion, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Celltrion, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Celltrion, Inc. Snapshot 5
Celltrion, Inc. Overview 5
Key Information 5
Key Facts 5
Celltrion, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Celltrion, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Celltrion, Inc. - Pipeline Products Glance 13
Celltrion, Inc. - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Celltrion, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Celltrion, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Celltrion, Inc. - Drug Profiles 19
infliximab biosimilar 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
rituximab biosimilar 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
trastuzumab biosimilar 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CTP-27 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
adalimumab biosimilar 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
bevacizumab biosimilar 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
cetuximab biosimilar 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CTP-19 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CTP-26 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
etanercept biosimilar 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
palivizumab biosimilar 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CTP-24 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CTP-25 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Celltrion, Inc. - Pipeline Analysis 35
Celltrion, Inc. - Pipeline Products by Target 35
Celltrion, Inc. - Pipeline Products by Route of Administration 36
Celltrion, Inc. - Pipeline Products by Molecule Type 37
Celltrion, Inc. - Pipeline Products by Mechanism of Action 38
Celltrion, Inc. - Recent Pipeline Updates 39
Celltrion, Inc. - Dormant Projects 43
Celltrion, Inc. - Dormant Projects 43
Celltrion, Inc. - Company Statement 44
Celltrion, Inc. - Locations And Subsidiaries 45
Head Office 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Celltrion, Inc., Key Information 5
Celltrion, Inc., Key Facts 5
Celltrion, Inc. - Pipeline by Indication, 2015 7
Celltrion, Inc. - Pipeline by Stage of Development, 2015 9
Celltrion, Inc. - Monotherapy Products in Pipeline, 2015 10
Celltrion, Inc. - Partnered Products in Pipeline, 2015 11
Celltrion, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 12
Celltrion, Inc. - Pre-Registration, 2015 13
Celltrion, Inc. - Phase III, 2015 14
Celltrion, Inc. - Phase II, 2015 15
Celltrion, Inc. - Phase I, 2015 16
Celltrion, Inc. - Preclinical, 2015 17
Celltrion, Inc. - Discovery, 2015 18
Celltrion, Inc. - Pipeline by Target, 2015 35
Celltrion, Inc. - Pipeline by Route of Administration, 2015 36
Celltrion, Inc. - Pipeline by Molecule Type, 2015 37
Celltrion, Inc. - Pipeline Products by Mechanism of Action, 2015 38
Celltrion, Inc. - Recent Pipeline Updates, 2015 39
Celltrion, Inc. - Dormant Developmental Projects,2015 43